Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

10. oktober 2009 oppdatert av: Pfizer

An Open-Label Two-Part Randomized, Crossover Study Of The Pharmacokinetics Of CE-224,535 Administered As Controlled And Immediate Release Formulations In Healthy Volunteers

The study will try, in 2 separate parts, each using 12 research subjects, to see how a new form of the pill CE 224,535 gets released into the bloodstream and whether that is affected by food. In each part, subjects will switch among 4 treatment periods to take either different forms of the pill(s) or the same form either after fasting or eating a meal. The second part will only happen depending on whether the sponsor believes it is needed and will use separate subject than the first part.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

11

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Connecticut
      • New Haven, Connecticut, Forente stater, 06511
        • Pfizer Investigational Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 55 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • aged 18-55 and healthy

Exclusion Criteria:

  • severe chronic or uncontrolled medical or psychiatric conditions, including drug abuse
  • pregnant or wanting to become pregnant

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part1; controlled release formulation 4; 250 mg
one 250 mg controlled release tablet, once in the morning, in fasted state
one 250mg tablet, once in the morning in fasted state
Andre navn:
  • Part 1;Treatment A
2x250 mg tablets, once in the morning, in fasted state
Andre navn:
  • Part 1;Treatment B
4x250mg tablets, once in the morning, in fasted state
Andre navn:
  • Part 1;Treatment C
2x250mg tab, once in the morning, after being fed a high fat meal
Andre navn:
  • Part 1;Treatment D
4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
Andre navn:
  • Part 2;Treatment E
4x125 mg IR once in the morning after being fed a high fat meal
Andre navn:
  • Part 2; Treatment F
Eksperimentell: Part1; controlled release formulation 4; 500 mg
2x250 mg, once in the morning, in fasted state
one 250mg tablet, once in the morning in fasted state
Andre navn:
  • Part 1;Treatment A
2x250 mg tablets, once in the morning, in fasted state
Andre navn:
  • Part 1;Treatment B
4x250mg tablets, once in the morning, in fasted state
Andre navn:
  • Part 1;Treatment C
2x250mg tab, once in the morning, after being fed a high fat meal
Andre navn:
  • Part 1;Treatment D
4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
Andre navn:
  • Part 2;Treatment E
4x125 mg IR once in the morning after being fed a high fat meal
Andre navn:
  • Part 2; Treatment F
Eksperimentell: Part 1; controlled release formula 4; 1000 mg
4x250 mg tabs, once in the morning, in fasted state
one 250mg tablet, once in the morning in fasted state
Andre navn:
  • Part 1;Treatment A
2x250 mg tablets, once in the morning, in fasted state
Andre navn:
  • Part 1;Treatment B
4x250mg tablets, once in the morning, in fasted state
Andre navn:
  • Part 1;Treatment C
2x250mg tab, once in the morning, after being fed a high fat meal
Andre navn:
  • Part 1;Treatment D
4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
Andre navn:
  • Part 2;Treatment E
4x125 mg IR once in the morning after being fed a high fat meal
Andre navn:
  • Part 2; Treatment F
Eksperimentell: Part 1; controlled release formulation 4; 500 mg FED
2x250 mg, once in the morning , in fed state
one 250mg tablet, once in the morning in fasted state
Andre navn:
  • Part 1;Treatment A
2x250 mg tablets, once in the morning, in fasted state
Andre navn:
  • Part 1;Treatment B
4x250mg tablets, once in the morning, in fasted state
Andre navn:
  • Part 1;Treatment C
2x250mg tab, once in the morning, after being fed a high fat meal
Andre navn:
  • Part 1;Treatment D
4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
Andre navn:
  • Part 2;Treatment E
4x125 mg IR once in the morning after being fed a high fat meal
Andre navn:
  • Part 2; Treatment F
Eksperimentell: Part 2; IR formulation 500mg
4x125 mg tab of current formulation , once in the morning in the fasted state. This arm will occur as Part 2, only as needed, pending results of Part 1
one 250mg tablet, once in the morning in fasted state
Andre navn:
  • Part 1;Treatment A
2x250 mg tablets, once in the morning, in fasted state
Andre navn:
  • Part 1;Treatment B
4x250mg tablets, once in the morning, in fasted state
Andre navn:
  • Part 1;Treatment C
2x250mg tab, once in the morning, after being fed a high fat meal
Andre navn:
  • Part 1;Treatment D
4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
Andre navn:
  • Part 2;Treatment E
4x125 mg IR once in the morning after being fed a high fat meal
Andre navn:
  • Part 2; Treatment F
Eksperimentell: Part 2; IR formulation, 500 mg FED
4x125 mg once in the morning in the fed state. This arm will occur as part of Part 2,only as needed, pending results of Part 1.
one 250mg tablet, once in the morning in fasted state
Andre navn:
  • Part 1;Treatment A
2x250 mg tablets, once in the morning, in fasted state
Andre navn:
  • Part 1;Treatment B
4x250mg tablets, once in the morning, in fasted state
Andre navn:
  • Part 1;Treatment C
2x250mg tab, once in the morning, after being fed a high fat meal
Andre navn:
  • Part 1;Treatment D
4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
Andre navn:
  • Part 2;Treatment E
4x125 mg IR once in the morning after being fed a high fat meal
Andre navn:
  • Part 2; Treatment F
Eksperimentell: Part 2; controlled release formulation 5;500 mg, FASTED
2x250 controlled release formulation 5 tabs once in the morning in the fasted state. This arm will only occur as part of Part 2, pending results of Part 1.
2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
Andre navn:
  • Part 2; Treatment G
2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
Andre navn:
  • Part 2; Treatment H
Eksperimentell: Part 2; controlled release formulation 5;500 mg, FED
2x250 mg controlled release formulation 5 tabs once in the morning in the fed state. This arm will only occur as part of Part 2 pending results of Part 1
2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
Andre navn:
  • Part 2; Treatment G
2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
Andre navn:
  • Part 2; Treatment H

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
pharmacokinetic parameters: Tmax, Cmax, AUClast, AUC(0-00), C24, t1/2
Tidsramme: 48 hrs
48 hrs

Sekundære resultatmål

Resultatmål
Tidsramme
safety parameters including: renal and liver function, blood counts, electrolytes, ECG, and pregnancy testing
Tidsramme: 48 hrs
48 hrs

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. januar 2009

Primær fullføring (Faktiske)

1. mars 2009

Studiet fullført (Faktiske)

1. mars 2009

Datoer for studieregistrering

Først innsendt

2. februar 2009

Først innsendt som oppfylte QC-kriteriene

5. februar 2009

Først lagt ut (Anslag)

6. februar 2009

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

14. oktober 2009

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. oktober 2009

Sist bekreftet

1. oktober 2009

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere